BAY 43-9006 IN COMBINATION WITH CETUXIMAB AND IRINOTECAN

BAY 43-9006 与西妥昔单抗和伊立替康组合

• 批准号: 7604649
• 负责人: Wells A. Messersmith
• 金额: --
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604649
• 关键词: BAY 43-9006; Biological; Cetuximab/Irinotecan; Clinical; Colorectal Cancer; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; Institution; Patients; Phase; Research; Research Personnel; Resources; Source; United States National Institutes of Health

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A phase I/II clinical, pharmacological, and biological study of BAY 43-9006 in combination with cetuximab and irinotecan in patients with advanced colorectal cancer.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 BAY 43-9006与西妥昔单抗和伊立替康联合治疗晚期结直肠癌患者的I/II期临床、药理学和生物学研究。